The Sigma-1 receptor (S1R) is a 26 kDa protein found in portions of the endoplasmic reticulum (ER) of cells. In the central nervous system the highest levels of the S1R (CNS) are found in the postsynaptic portions of cholinergic postsynaptic densities (C-terminals) of spinal cord motoneurons. The primary objective of this proposal is to evaluate the role of S1R in regulating the excitability of motoneurons. We hypothesize that the S1R plays a direct role in regulating motoneuron excitability by activation of SK and/or Kv2.1 potassium channels in C-terminals, the effect of which is to increase the amplitude of the afterhyperpolarization potential (AHP) and thereby to reduce the frequency and duration of action potential firing. We hypothesize that activation of S1R can increase longevity of ALS mice by acting as a neuromodulatory "brake" on motoneuron hyperexcitability and thereby to decrease intracellular stress. We will accomplish the goals of this proposal through the following specific aims:
Specific Aim 1 : To determine whether S1R modulates motoneuron excitability (Electrophysiology) and influences the amplitude of electrical activity of the gastrocnemius muscle. (Motor activity).
Specific Aim 2 : To establish that activation of S1R can retard the progression of motoneuron degeneration in a mouse model of ALS (Pathology) by a) assessing survival of a new mouse model SOD1 ALS/S1R KO compared to the SOD1 ALS/S1R WT mice and b) assessing survival of the SOD1 ALS/S1R KO and the SOD1 ALS/S1R WT mice in the presence and absence of agonists of the S1R. Targeting S1R can potentially establish a new therapeutic treatment for ALS.

Public Health Relevance

The hypothesis in this proposal is that the Sigma-1 receptor acts as a "brake" on neuronal excitability. With a reduction in neuronal excitability motoneurons experience less cellular damage and thereby remain functional for a longer period during the development of Amyotrophic Lateral Sclerosis (Lou Gehrig's disease). We expect that activating the Sigma-1 receptor with specific drugs will further reduce cellular damage and lead to new treatment strategies for Lou Gehrig's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS075820-01A1
Application #
8302679
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Gubitz, Amelie
Project Start
2012-01-15
Project End
2013-12-31
Budget Start
2012-01-15
Budget End
2012-12-31
Support Year
1
Fiscal Year
2012
Total Cost
$225,750
Indirect Cost
$75,750
Name
University of Wisconsin Madison
Department
Pharmacology
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Chu, Uyen B; Vorperian, Sevahn K; Satyshur, Kenneth et al. (2014) Noncompetitive inhibition of indolethylamine-N-methyltransferase by N,N-dimethyltryptamine and N,N-dimethylaminopropyltryptamine. Biochemistry 53:2956-65
Gromek, Katarzyna A; Suchy, Fabian P; Meddaugh, Hannah R et al. (2014) The oligomeric states of the purified sigma-1 receptor are stabilized by ligands. J Biol Chem 289:20333-44
Torres, B; Ruoho, A E (2014) N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux. Neuroscience 259:194-202
Mavlyutov, T A; Epstein, M L; Verbny, Y I et al. (2013) Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience 240:129-34